Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

The Pap smear is perhaps the most well-known method of cervical cancer screening. First introduced in 1928 and widely adopted ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

Highlighting the dire consequences if no action is taken, he said, "If we do not act, Pakistan will face over 11 million HCV cases by 2035, leading to 500,000 plus liver cirrhosis cases, over 100,000 ...